Truist Securities Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $50
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Srikripa Devarakonda has initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and a price target of $50.
June 30, 2023 | 10:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kymera Therapeutics has been given a Buy rating and a price target of $50 by Truist Securities.
The Buy rating and price target of $50 announced by Truist Securities for Kymera Therapeutics is likely to have a positive impact on the company's stock in the short term. This is because such ratings and price targets often influence investor sentiment and can lead to increased buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100